At what enterprise value was CORIN GROUP acquired in 2018?

During the acquisition of CORIN GROUP by PERMIRA in 2018, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 300M - 700M GBP. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of CORIN GROUP when it was acquired by PERMIRA?

The estimated EV/EBITDA multiple for CORIN GROUP is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was CORIN GROUP acquired by PERMIRA?

CORIN GROUP was acquired by PERMIRA in 2018.

What was the revenue of CORIN GROUP at the time of the deal?

The revenue of CORIN GROUP at the time of the deal is estimated to be in the range of 100M - 200M GBP. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of CORIN GROUP during the acquisition?

CORIN GROUP's EBITDA is estimated to be in the range of 10M - 30M GBP. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the CORIN GROUP acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the CORIN GROUP deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.permira.com/news-and-insights/announcements/permira-funds-to-acquire-corin-a-leading-orthopaedic-company

← DATABASE

Home Database Healthcare & PharmaCORIN GROUP

05/2018

CORIN GROUP acquired by PERMIRA

UNITED KINGDOM Life Sciences / Medical Devices / Implants & Prosthetics EV 300M - 700M GBP

Context

Permira, the global private equity firm, acquired a majority stake in Corin Group, a UK-based leader in orthopaedic innovation, from a consortium of investors including DeA Capital, Hunt Capital, and IP (Investimenti e Partecipazioni). Permira's thesis was centered on accelerating Corin's international scale—particularly in the US and Australian markets—and fueling an aggressive buy-and-build strategy to integrate digital health and robotic capabilities into the core implant business. This approach aimed to position Corin as a "Challenger OEM" capable of disrupting larger incumbents through superior product innovation and data-driven patient monitoring.

CORIN GROUP, which reported an EBITDA margin of in 2017, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Corin is an international orthopaedic company that designs, manufactures, and distributes a wide range of joint replacement implants (hip, knee, ankle, and shoulder). It is recognized for its "Connected Orthopaedic Insight" strategy, which integrates clinically proven implants with advanced digital technologies and robotic-assisted surgical platforms to improve patient outcomes and surgical precision.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (GBP)

Year

Rev

EBITDA

EBIT

2017

2016

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
10/2018	BRIDGEPOINT	HTL BIOTECHNOLOGY	FRANCE	CDMO
08/2018	DENTRESSANGLE	ACTEON	FRANCE	Medical Devices
05/2018	NN	PARAGON MEDICAL	UNITED STATES	Medical Devices
05/2018	Zoetis	Abaxis	UNITED STATES	Diagnostic Equipment
12/2017	PERKINELMER	EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS	GERMANY	Diagnostic Equipment
10/2017	UI INVESTISSEMENT / BPIFRANCE	THERADIAL	FRANCE	Medical Devices
10/2017	CVC	SEBIA	FRANCE	Diagnostic Equipment
09/2017	FRESENIUS	NXSTAGE MEDICAL	UNITED STATES	Diagnostic Equipment
06/2017	EQT PARTNERS	OTTOBOCK	GERMANY	Implants & Prosthetics
06/2017	CHARTERHOUSE	SERB	BELGIUM	Pharma & Biotech

REFERENCES

Valuation range: EV 300M - 700M GBP

Revenue range: 100M - 200M GBP

EBITDA range: 10M - 30M GBP

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of CORIN GROUP by PERMIRA are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: corin group

Acquirer: permira